Ferroportin inhibitors

VIT-2763

 

Update: 27 September 2019

No update available

 

Update: 30 July 2019

Results announced during 24^th Annual Congress of the European Hematology Association show that treatment with single and multiple oral doses of VIT-2763 were well tolerated in healthy subjects, decreasing the iron levels in circulation.

A proof of concept study in patients with β-thalassaemia is supported by these results.

Sources:

https://library.ehaweb.org/eha/2019/24th/266305/frank.richard.first-in-human.single-.and.multiple-ascending.dose.study.of.the.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dferroportin

 

Update: 30 May 2019

No update available.

 

 Update: 01 February 2019

A randomized, controlled, multi-centred phase 2 proof-of-concept trial will begin in the second half of 2019 to assess the effectiveness of the oral ferroportin inhibitor (VIT-2763) on iron overload in β-thalassaemia patients.

Phase 1 trials have shown positive results with a consistent lower serum iron for up to 24 hours post-dose. The results are dose-dependent.

Treatment with VIT-2763 can improve iron metabolism and the production of RBCs.

Sources:

http://www.viforpharma.com/~/media/Files/V/Vifor-Pharma/documents/en/media-releases/2019/pr-vifor-pharma-ferroportin-inhibitor-en.pdf